Clinical trial
Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis
NCT07565701 is registered in ClinicalTrials.gov with Geoff Block as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis
- Lead sponsor
- Geoff Block
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- April 30, 2026
- Completion date
- June 30, 2027
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
anemia associated with chronic kidney disease